SCPHARMACEUTICALS INC. - COMMON STOCK

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

19 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

12 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease

06 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

26 Feb 2025 16:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05 Feb 2025 16:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

10 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

13 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

15 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

04 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

14 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

12 Aug 2024 09:48:52 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

12 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

12 Aug 2024 06:04:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

12 Aug 2024 06:02:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

12 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Announce Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

08 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease

25 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

29 May 2024 16:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

14 May 2024 16:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 May 2024 16:05:00 By Nasdaq GlobeNewswire